CW Labs partners with McLean Hospital on CBD efficacy research

The Charlotte’s Web division will work with McLean’s MIND Program to support two clinical studies.
David Salazar
Managing Editor
David Salazar profile picture

CW Labs, a division of Charlotte’s Web, is partnering with a Harvard Medical School affiliate to research the efficacy of CBD. The Buffalo, N.Y.-based division will be offering funding and product support to McLean Hospital for two clinical trials overseen by Staci Gruber, associate professor of psychiatry at Harvard Medical School and director of McLean’s MIND Program. 

The two trials, whose results will be published in 2022, will evaluate the efficacy of custom-formulated, hemp-derived CBD products. Gruber also is conducting several other studies simultaneously, including a longitudinal observational study of veterans using a Charlotte’s Web product. 

MIND is the Marijuana Investigations for Neuroscientific Discovery Program, which was established in 2014. The program looks to clarify the specific aspects of medical cannabis use and is designed to support a wide range of study designs to create ecologically valid and empirically sound data to help bring science and policy closer in sync. 

"We are honored to be working with Dr. Gruber, Harvard Medical School and McLean Hospital on these important clinical trials," said Tim Orr, president of Charlotte's Web's CW Labs division. "Charlotte's Web remains dedicated to supporting third-party research on hemp CBD investigated by some of the country's top scientists."

Boulder, Colo.-based Charlotte’s Web operates CW Labs as its research and development division, focusing on advancing science around phytocannabinoids, terpenes and flavonoid compounds. The division is headquartered at the University of Buffalo’s Jacobs School of Medicine and The Center for Integrated Global Biomedical Studies as part of the school’s Hauptmann Woodward Research Institute.